Tech Company Financing Transactions
X-Vax Technology Funding Round
X-Vax Technology closed a $56 million Series A funding round on 7/24/2019. Backers included Adjuvant Capital, Alexandria Venture Investments and Founders Fund.
Transaction Overview
Company Name
Announced On
7/24/2019
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead program, a vaccine candidate against herpes, called ?gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
601 Heritage Dr. 138
Jupiter, FL 33458
USA
Jupiter, FL 33458
USA
Phone
Website
Email Address
Overview
X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ulf Wiinberg
Chief Financial Officer
Jacob Uittenbogaard
Chief Operating Officer
Andreas Eggert
VP - Bus. Development
Richard Kenney
VP - Regulatory Affairs
Clare Kahn
Browse more venture capital transactions:
Prev: 7/24/2019: QOMPLX venture capital transaction
Next: 7/24/2019: Inventables venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs